Ann-Hunter Van Kirk

Senior Equity Research Analyst Biopharmaceuticals • Bloomberg Intelligence

Ann-Hunter Van Kirk is a Senior Equity Research Analyst at Bloomberg Intelligence covering the Biopharmaceutical sector with a focus on gene editing, animal health, neuroscience, generics, and eyecare companies. A.H. brings a long career of sell-side healthcare equity research experience from prior positions at Barclays, BMO Capital Markets, and Cantor Fitzgerald. Ms Van Kirk holds a master’s degree from the London School of Economics and two bachelor’s degrees from Southern Methodist University with honours.

Also speaking

Ben Doak

Head of Innovative Treatments • NHS England

Evren Alici

Head of Cell and Gene Therapy Group, Department of Medicine • Karolinska Institutet

Jacqueline Barry

Chief Clinical Officer • CGT Catapult

Event Info


2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.

Innovation Zone

Find out more about the Innovation Zone at Advanced Therapies Europe.